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Summary The present report describes the non-haematological toxicity and the influence of growth factor administration on haematological
toxicity and haematopoietic recovery observed after high-dose carboplatin (1200 mg m-2), etoposide (900 mg m-2) and melphalan (100 mg
m-2) (CEM) followed by peripheral blood progenitor cell transplantation (PBPCT) in 40 patients with high-risk cancer during their first-line
treatment. PBPCs were collected during the previous outpatient induction chemotherapy programme by leukaphereses. CEM administration
with PBPCT was associated with low non-haematological toxicity and the only significant toxicity consisted of a reversible grade III/IV
increase in liver enzymes in 32% of the patients. Haematopoietic recovery was very fast in all patients and the administration of granulocyte
colony-stimulating factor (G-CSF) plus erythropoietin (EPO) or granulocyte-macrophage colony-stimulating factor (GM-CSF) plus EPO after
PBPCT significantly reduced haematological toxicity, abrogated antibiotic administration during neutropenia and significantly reduced hospital
stay and patient's hospital charge compared with patients treated with PBPCT only. None of the patients died early of CEM plus PBPCT-
related complications. Low non-haematological toxicity and accelerated haematopoietic recovery renders CEM with PBPC/growth factor
support an acceptable therapeutic approach in an adjuvant or neoadjuvant setting.
Keywords: adjuvant or neoadjuvant high-dose chemotherapy; peripheral blood progenitor cell support; growth factor
High-dose chemotherapy (HDC) with autologous haematopoietic
progenitor support is a promising approach for increasing the dose
intensity of first-line treatment in patients with high-risk cancer
who respond to conventional therapy (McMillan et al, 1991; Peters
et al, 1993a; Wheeler et al, 1993; Ayash et al, 1994; Gianni et al,
1994; Benedetti Panici et al, 1995). Unfortunately, HDC is limited
by significant morbidity and mortality related to haematological
and non-haematological toxicities. Hence, the development of
novel intensive treatment programmes with acceptable toxicity is
required to clarify the role ofhigh-dose polychemotherapy during
the initial treatment of high-risk cancer. The use of carboplatin
(CBDCA) with haematopoietic progenitor cell support in the
intensification phase has been suggested in patients suffering from
several solid tumours. CBDCA shows a similar activity to
cisplatin (CDDP) (Ozols et al, 1985), but it causes less nausea and
vomiting and less neurotoxicity, its dose-limiting toxicity being
myelosuppression. In fact, the lack ofnon-haematological toxicity
makes CBDCA a potentially useful drug in a high-dose chemo-
therapy setting, when recovery from myelosuppression can be
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accomplished by the use of adequate haematological support.
Etoposide (VP16) is a semi-synthetic derivative of podophyllo-
toxin with significant cytotoxic activity in a broad spectrum of
human tumours, including small-cell lung cancer, testicular
cancer, lymphoma, ovarian cancer, breast cancer and paediatric
tumours (Aisner and Lee, 1991). A relevant characteristic ofVP16
is its low non-haematological toxicity. VP16 may be combined
with CBDCA because it shows synergistic activity both in vivo
and in vitro with platinum compounds (Schabel et al, 1979;
Loehrer et al, 1986), and the combination has produced responses
in recurrent childhood tumours (Castello et al, 1990). Melphalan
(L-PAM) is one ofthe most effective single alkylating chemother-
apeutic agents against epithelial ovarian carcinoma (Piver, 1984)
and shows a steep dose-response curve in breast carcinoma in
vitro and in vivo (Vincent et al, 1988; Ayash et al, 1991). The
effectiveness ofthis drug is dose dependent and it shows a promi-
nent haematological toxicity. Each of the three above-mentioned
agents exerts a different cell cycle-specific activity and they do not
have significant oroverlapping non-haematological toxicities. The
present report describes the non-haematological toxicity and the
influence of growth factor administration on haematological
toxicity and haematopoietic recovery observed after high-dose
CBDCA, VP16 and L-PAM (CEM) followed by the infusion
of haematopoietic progenitor cells in patients with high-risk
cancer. CEM was administered as a consolidation therapy during
the first-line treatment of 26 patients with ovarian cancer (OvCa)
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Table 1 Patient characteristics
No. of patients enrolled 40
Median age (years) 48
Range 35-60
Diagnosis
Breast cancer (n = 14)
Stage 1I1 3
High-risk stage 11 11
Ovarian cancer (n = 26)
Stage III 22
Stage IV 4
and 14 patients with breast cancer (BrCa) and it was followed by
peripheral blood progenitor cell transplantation (PBPCT) with or
without post-PBPCT growth factor administration.
PATIENTS AND METHODS
Patients
From June 1993 to December 1995, 24 patients with stage III or
IV ovarian carcinoma (OvCa) with a residual tumour < 1 cm after
cytoreductive or intervention cytoreductive surgery and 14
patients with stage II or III resectable breast cancer (BrCa) with
eight or more involved axillary lymph nodes, ranging in age from
35 to 60 years (median 48 years), were enrolled in this phase I/II
study (Table 1). All patients were previously untreated with
chemotherapy or radiotherapy. Eligibility criteria included a
performance status of 0-2 (WHO scale), adequate pulmonary,
cardiac, hepatic and renal function, absence of underlying infec-
tions, a polymorphonuclear leucocyte count > 2 x 109 1-' and a
platelet count > 100 x 109 1-'. The study was approved by the
Hospital Human Investigation Review Board and written informed
consent was obtained from all patients.
Treatment plan
All patients were treated with an outpatient chemotherapy induction
programme followed by high-dose chemotherapy consolidation
with CEM, followed by the reinfusion of peripheral blood progen-
itor cells (PBPCs) collected after low-dose cyclophosphamide (LD-
Cy) plus recombinant human G-CSF (rhG-CSF) in combination
with cisplatin (CDDP) or epirubicin (EPR). Patients with OvCa
received 1500 mg m-2 LD-Cy on day I and 100 mg m-2 CDDP
on day 1. Patients with BrCa received 1500 mg m-2 LD-Cy on
day 1 and 120mg m-2 EPR on day 1. Twenty-four hours after
chemotherapy all patients received 5 gg kg-' day-' rhG-CSF
(Neupogen, DompeBiotec, Milan, Italy) subcutaneously. RhG-CSF
treatment was continued until complete blood cell recovery was
obtained and PBPC collections were completed. PBPCs were
collected by leukaphereses using the Fresenius AS104 blood
cell separator (Fresenius, St Wendel, Germany) as previously
described (Pierelli et al, 1993). Collections were started on day 12
afterLD-Cy plus rhG-CSF in combination with CDDP or EPR and
performed on consecutive days until a minimum of 4 x 108 kg-'
peripheral blood mononuclear cells were collected per patient, as
previously described (Menichella et al, 1994). A blood volume of
about 91 was processed for single collection and peripheral
venepunctures were used as vascular access in all patients. The
amount of colony-forming unit granulocyte-macrophage (CFU-
GM) collected per patient was evaluated as previously described
(Pierelli et al, 1993). All patients with OvCa were treated with three
additional courses ofconventional dose 600mgm-2Cy onday 1 and
100 mg m-2 CDDP on day 1, administered every 15 days, after the
administration ofLD-Cy + CDDP. After the administration of LD-
Cy + EPR, all patients with BrCa were treated with four additional
courses ofconventional-dose 600 mg mi-2 Cy on day 1 and 120 mg
m-2EPR on day 1, administered every 15 days. In all patients, CEM
consisted ofthe administration ofcumulative doses of 1200 mg m-2
CBDCA, 900mg n-2 VP16 and 100mg m-2 L-PAM fromday -4 to
day - 1. On day 0, PBPCs were reinfused into the patients, immedi-
ately after thawing, through a central venous catheter. The infusion
ofthe wholegraftwascompletedwithin aperiodof24hin all cases.
Ten consecutive patients (group A) did not receive haematopoietic
growth factorfollowing PBPCT. Fifteenconsecutivepatients (group
B) were treated 24 h after the infusion of PBPCs with rhG-CSF
(Neupogen) at a dose of5 ,ug kg-' subcutaneously (s.c.) every 24 h
until day + 12 and with recombinant human erythropoietin (rhEPO;
Globuren, Dompe Biotec, Milan, Italy) at a dose of 150 IU kg-' s.c.
every 48 h until day + 11. Twenty-four hours after the infusion of
PBPCs, 15 consecutive patients (group C) received recombinant
human granulocyte-macrophage colony-stimulating factor (rhGM-
CSF; Mielogen Schering Plough, Milan, Italy) at adose of5 ggkg-'
s.c. every 24 h until day + 12 and rhEPO (Globuren) at a dose of
150 IU kg-' s.c. every 48 h until day + 11. All patients were nursed
in conventional single-bed rooms and access to patients' rooms
required masks, gloves, gowns and shoe covers. Patients received
Table 2 Non-haematological toxicitya
Grade
Toxic effect 0 1 11 ll IV
Mucositis 22 (56%) 18 (44%)
Nausea/vomiting 11 (28%) 24 (60%) 5 (12%)
Enteritis 6 (16%) 16 (40%) 16 (40%) 2 (4%)
Elevation in transaminases 2 (4%) 11 (28%) 14 (36%) 8 (20%) 5 (12%)
Elevation in bilirubin 40 (100%)
Haemorrhagic cystitis 34 (84%) 6 (16%)
Cardiac toxicity 40 (100%)
Renal toxicity 25 (64%) 13 (32%) 2 (4%)
Overall mortality 0
aNon-haematological toxicity was evaluated according to the WHO scale. There were 40 evaluable patients.
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Table 3 Haematopoietic recovery and haematological toxicity
PBPCT PBPCT +G-CSF + EPO PBPCT + GM-CSF + EPO P
(A) (B) (C)
No. of patients 10 15 15
Age (years)range 44 (35-56) 48 (36-59) 53(39-60) 0.12
MNC (x 108 kg-') 8 (5-12) 6 (4-10) 6 (3-10) 0.11
CFU-GM x 104 kg-' 46 (14-120) 35 (12-130) 25 (10-45) 0.24
Days to:
< 0.0001
WBC > 1 x 109 1-1 11 (9-12) 9 (8-10) 10 (9-12) A vsB < 0.0001, A vsC 0.130, B vsC 0.0089
< 0.0001
PMN > 0.5 x 109 1-1 11 (9-12) 8 (7-10) 10 (9-12) A vs B < 0.0001, A vsC 0.215, B vsC 0.0013
0.0008
PLT > 50 x 1091-1 11.5 (10-12) 10 (9-11) 11 (10-15) A vs B 0.0594, A vsC 0.609, B vsC 0.0032
Days with:
0.0026
WBC < 1 x 109 I-' 7.5 (7-11) 6 (4-9) 6 (4-9) A vs B 0.0036, A vsC 0.0192, B vsC 0.897
0.0002
PMN < 0.5 x 109 1-1 8 (7-9) 6 (3-9) 6 (5-9) A vs B 0.0003, A vs C 0.104, B vs C 0.0684
0.0018
PMN < 0.2 x 109 1-1 7 (5-8) 5 (3-8) 6 (4-7) A vsB 0.0022, A vsC 0.2297, B vsC 0.1199
PBPCT, peripheral blood progenitor cell transplantation; G-CSF, granulocyte colony-stimulating factor; EPO, erythropoietin; GM-CSF, granulocyte-macrophage
colony-stimulating factor; MNC, mononuclear cells; CFU-GM, colonyforming unit granulocyte-macrophage; WBC, white blood cells; PMN, polymorphonuclear
leucocytes; PLT, platelets. Results are presented as the median value (range). aComparisons were made by Kruskal-Wallis and Mann-Whitney U non-
parametric tests.
Table 4 Clinical management
PBPCT PBPCT + G-CSF + EPO PBPCT +GM-CSF + EPO P
(A) (B) (C)
No. of patients 10 15 15
Days with:
< 0.0001
fever> 380C 4 (0-12) 0 (0-0) 3 (0-4) A vs B < 0.0001, A vsC 0.1858, B vsC 0.0066
Days on:
< 0.0001
antibiotics 7.5 (0-17) 0 (0-0) 0 (0-0) A vs B < 0.0001, A vsC < 0.0001
RBC transfusions 0 (0-1) 0 (0-0) 0 (0-1) 0.42
0.0378
PLTtransfusions 2 (1-3) 1 (1-2) 1.5 (1-4) A vsB 0.0503, A vsC0.6821, B vsC 0.2379
Days in:
0.0054
hospital 20 (18-38) 18 (14-22) 16 (13-22) A vs B 0.0357, A vsC 0.0069, B vsC 0.5730
PBPCT, peripheral blood progenitor cell transplantation; G-CSF, granulocyte colony-stimulating factor; EPO, erythropoietin; GM-CSF, granulocyte-macrophage
colony-stimulating factor; RBC, red blood cells; PLT, platelets. Results are presented as the median value (range). aComparisons were made by Kruskal-Wallis
and Mann-Whitney Unon-parametric tests.
parenteral hyperalimentation fromHDC tocompletehaematopoietic
recovery. Antimicrobial and antifungal prophylaxis consisted of
the daily administration ofciprofloxacin (1000 mg day-'), flucona-
zole (150 mg day-'), acyclovir (800 mg day-') and trimethop-
rim/sulphamethoxazole (960 mg day-') twice a week from CEM to
day + 40. During the period of neutropenia, patients were started
immediately on broad-spectrum antibiotics when they had a
sustained fever of > 38°C for more than 12 h and amphotericin B
was added when fever persisted for more than 7 days in spite of
antibiotic treatment. Irradiated red blood cells (RBCs) and single
donorplatelets (PLTs) were transfused to maintain Hb count> 8.5 g
dl-' and PLT count > 20 x 109 1-'. Haematopoietic engraftment was
defined as the number ofdays necessary to reach white blood cells
(WBCs) > 1 x 109 1-', polymorphonuclear leucocytes (PMNs) > 0.5
x 109 1-1 and PLTs >50 x 109 1-'. All patients were discharged from
the hospital when their peripheral PMNs and PLT counts reached a
value of 1 x 109 1-1 and 50 x 109 1-', respectively, in the absence of
suspected ordocumented infectious complications.
Toxicities were graded using the standard World Health
Organization (WHO) system.
Statistical analysis
Comparisons between groups of patients were performed by the
Kruskal-Wallis and Mann-Whitney U non-parametric tests. A
P-value < 0.05 was considered significant.
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Table 5 Comparison of published non-haematological toxicitiesa of etoposide/carboplatin-based high-dose chemotherapy for poor prognosis malignancies
Reference Regimen No. of patients Enteritis Mucositis Nauseavomiting Renal Hepatic Overall mortality
Present study CEM 40 4% 0% 12% 0% 32% 0%
Ibrahim et al (1993) CECy 25 85% 42% 85% 0% 14% 8%
Nichols et al (1989) CE 33 9% 8% - 9% 15% 21%
Lotz et al (1995) ICE 39 43% 34% - 8% 8% 18%
Fields et al (1994) ICE 115 44% 64% 38% 2% 30% 5%
aWHO grade .3. C, carboplatin; E, etoposide; M, melphalan; Cy, cyclophosphamide; I, ifosfamide.
RESULTS
PBPC infusion following CEM
A median of 6.0 x 108 mononuclear cells (MNCs) kg-' (range
3-12) and a median of 30 x 104 colony-forming unit granulo-
cyte-macrophage CFU-GM kg-' (range 10-330) were reinfused in
40 patients 24 h after CEM administration. The infusion of the
whole dose of PBPCs was completed within a period of 24 h and
the infusion of thawed PBPCs was generally well tolerated in all
patients.
Non-haematological toxicity
Overall, the administration of CEM was well tolerated and the
non-haematological toxicities were never life-threatening. Data
relative to non-haematological toxicity are detailed in Table 2.
Mild to moderate enteritis (grade I and II) was observed in 80%
(32 patients) of the patients, while only 4% (two patients) of the
patients had grade III. Most of the patients (88%, 35 patients)
experienced grade I/II nausea and vomiting and only 12% (five
patients) ofthe patients had grade III. An increase in liver enzymes
was observed in most patients (96%, 38 patients), and 64% (25
patients) of the patients had grade I/II toxicity, 20% (eight
patients) had grade III and 12% (five patients) had grade IV.
Mucositis was observed in only 44% (18 patients) of the patients
and it was grade I. Mild renal toxicity (consisting of grade I
proteinuria) was observed in 36% (15 patients) of the patients.
Only six patients (16%) showed mild haemorrhagic cystitis with
grade I haematuria. None of the patients experienced any cardiac
toxicity.
Influence of growth factor administration on
haematological toxicity and haematopoietic recovery
As detailed in Patients and methods, haematopoietic support
consisted ofPBPC infusion alone in ten patients (group A), PBPC
infusion and G-CSF plus EPO administration in 15 patients (group
B) and PBPC infusion and GM-CSF plus EPO administration in
15 patients (group C) (Tables 3 and 4). All groups ofpatients were
balanced with respect to age, CFU-GM kg-1 and MNC kg-' infused
doses. After the administration of CEM combination, severe
myelosuppression occurred in all patients. All groups of patients
we studied recovered promptly from myelosuppression, but group
B achieved PMN > 0.5 x 109 1-1 and WBC > 1 x 109 1-1 signifi-
cantly earlierthan groups A and C (Table 3). Additionally, group B
recovered 50 x 109 1-' PLTs significantly faster than group C and
faster than group A with a borderline significance (Table 3). In the
same way, the number ofdays with PMN < 0.2 x 1091-1 and PMN
< 0.5 x 1091-1 were significantly lower for group B compared with
group A (Table 3). Conversely, the number ofdays with WBC < 1
x 1091-' were significantly lower for groups B and C compared
with group A (Table 3). Group B patients required a lower number
of single-donor PLT transfusions with borderline significance
compared with group A (Table 4). Most of the patients did not
require RBC transfusions (Table 4). Figure 1 details the kinetics of
haematopoietic reconstitution ofeach patient group.
Fever and infection
Eighty per cent of the patients in group A and 90% ofthe patients
in group C developed fever. None of the patients in group B had
fever. A microbiologically documented infection was observed in
only one patient in group A (Candida glabrata). Fever episodes
required systemic antibiotic treatment in all group A patients,
while the intermittence of fever episodes in group C discouraged
the use of systemic antibiotics. As a consequence, in group B and
C patients systemic antibiotics were not administered (Table 4).
Hospital stay
Group B and C patients were discharged from the hospital after a
significantly shorter period of time than group A patients (Table
4). The median hospital stay (including the period required for
CEM administration) for group A patients was 20 days (range
18-38), for group B it was 18 days (range 14-22) and for group C
it was 16 days (range 13-22).
Survival
None of the patients treated with CEM and PBPCT died within
100 days after transplant of transplant-related complications. At
the present time, 32 patients (80%) are alive without evidence of
disease, with a median follow-up of 22 months (range 4-44) six
patients (15%) are alive with recurrent disease or residual disease
with a median follow-up of 20 months (range 15-34) and two
patients (5%) have died ofrecurrent disease. None ofthe patients
experienced long-term complications related to the transplant
procedure and all living patients show sustained haematopoiesis.
All patients with residual or recurrent disease underwent second-
line treatment and showed mild and predictable haematological
and non-haematological toxicities.
DISCUSSION
The present report describes the non-haematological toxicity and
the influence of growth factor administration on haematological
toxicity and haematopoietic recovery observed after high-dose
CEM with PBPCT in patients with high-risk ovarian or breast
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Figure Kinetics of haematopoietic reconstitution following peripheral blood progenitor transplantation (PBPCT) of the different patient groups we studied. Ten
consecutive patients did not receive any growth factor (PBPCT in the figure; group A in the text), 15 patients were treated with granulocyte colony-stimulating
factor + erythropoietin combination following PBPCT (PBPCT + G-CSF + EPO in the figure; group B in the text) and 15 patients with granulocyte-macrophage
colony-stimulating factor + erythropoietin combination (PBPCT + GM-CSF + EPO in the figure; group C in the text). The average blood counts following PBPCT
(day 0) observed in the patients included in the different groups have been plotted and compared. WBC, white blood cells; PMN, polymorphonuclear leucocytes;
PLT, platelets; Hb, haemoglobin
cancer who underwent late intensification during their first-line
treatment. A mild to moderate non-haematological toxicity was
observed in most patients after CEM and PBPCT, and none of the
patients had severe organ toxicities that discouraged the treatment
of additional patients. CEM administration did not cause any
cardiac, renal or bladder toxicities and a grade IV increase in
serum transaminases was observed in only 12% of the patients.
Grade II nausea and vomiting (observed in about 60% of the
patients) and grade 11I enteritis (observed in about 80% of the
patients) were the clinically relevant non-haematological toxicities
of this high-dose treatment. In terms of non-haematological tox-
icity, these results are similar to or better than those reported else-
where for other combinations of high-dose alkylating agents with
progenitor cell support in combination or not with etoposide
(Williams et al, 1987; Gaspard et al, 1988; Slease et al, 1988;
Vincent et al, 1988; Eder et al, 1990; Elias et al, 1991; Antman et
al, 1992; Williams et al, 1992; Siegert et al, 1994; Benedetti Panici
et al, 1995). Our results are better in terms of non-haematological
toxicity than those reported recently for patients with high-risk
cancer treated with ifosfamide, carboplatin and etoposide (Barnett
et al, 1993; Fields et al, 1994; Elias et al, 1995), high-dose
cyclophosphamide and etoposide (de Graaf et al, 1994), high-dose
cyclophosphamide and carboplatin (Spitzer et al, 1995) and with
cyclophosphamide, thiotepa and carboplatin (van der Wall et al,
1995) during their first-line therapy. In fact, the above-mentioned
studies reported a higher number of patients who experienced
grade III nausea/vomiting, grade III enteritis and grade III
mucositis. Additionally, the presence of high-dose cyclophos-
phamide in some of these regimens produced cardiac toxicity in
some patients. The absence of any cardiac toxicity and ofmoderate
or severe renal toxicity following CEM administration renders this
high-dose regimen particularly suitable for the treatment of those
patients who have previously been treated with cardiotoxic or
nephrotoxic agents, such as doxorubicin or CDDP, or in whom
PBPCs have been collected after high-dose cyclophosphamide. A
reasonable explanation of the low non-haematological toxicities
observed in our patients treated with CEM is the positive impact
of the incorporation of high-dose L-PAM in a high-dose
VP16/CBDCA-based regimen in which VP16 and CBDCA are not
administered at their maximal tolerated dose for a drug combina-
tion. Table 5 compares the severe non-haematological toxicities
observed by several authors following the administration of
VP16/CBDCA-based high-dose chemotherapy with those reported
in the present study. The comparison confirms the low contribu-
tion of L-PAM in increasing non-haematological toxicity and
underlines the absence of treatment-related mortality following
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CEM administration. On the other hand, haematological toxicity
after CEM administration was severe in all patients and WBCs
decreased below the value of 0.05 x 109 1- and PLTs below the
value of20 x 109 1- in all treated patients. However, we observed
a very rapid haematopoietic recovery in all treated patients so that
12 days after PBPC reinfusion all patients experienced the normal-
ization of WBC count and did not require any transfusional
support. As previously described (Menichella et al, 1994), the
quality ofthe graft collected in these patients, most ofwhom were
chemotherapy-naive at the time ofPBPC mobilization and collec-
tion, made it possible to obtain an accelerated haematopoietic
recovery in most patients, faster than that reported in several other
experiences of PBPC transplantation (Gianni et al, 1989;
Menichella et al, 1991; Elias et al, 1992; To et al, 1992; Henon et
al, 1992; Sheridan et al, 1992; Peters et al, 1993b; Sica et al, 1993;
Chao et al, 1993; Bensinger et al, 1993; Pierelli etal, 1994; Spitzer
et al, 1994; Shimazaki et al, 1994; Bishop et al, 1994). The present
study also shows that a significantly faster WBC, PMN and PLT
recovery can be achieved by administering G-CSF plus EPO after
PBPCT, as described previously (Pierelli et al, 1996). On the other
hand, a significant decrease in the number ofdays with WBC < 1
x 1091-' can be obtained by administering either G-CSF plus EPO
or GM-CSF plus EPO after PBPCT. In fact, the main advantage of
administering G-CSFplus EPO is a more rapidrecovery ofmature
granulocytes, while in GM-CSF plus EPO-treated patients the
persistence of an immature leucocyte population was observed by
us in the first days ofrecovery. Most ofthe patients did not require
RBC transfusion and patients treated with growth factors after
PBPCT had a less marked decline of Hb levels than patients
treated with PBPCT only (Figure 1). The administration of EPO
with G-CSF and GM-CSF after PBPCT probably abrogated the
previously described detrimental effect ofG-CSF and GM-CSF on
PLT recovery after PBPCT (Spitzer et al, 1994; Shimazaki et al,
1994; Bensinger et al, 1994), which could be caused by aprevalent
potentiation of myelopoiesis with a consensual progenitor cell
competition in vivo. Patients treated with growth factors did not
require systemic antibiotic therapy with the total abrogation of
neutropenic fever in G-CSF plus EPO-treated patients, while GM-
CSF plus EPO-treated patients experienced only episodes ofinter-
mittent hyperthermia, which did not meet the criteria for the start
of systemic antibiotic treatment. Only one patient in the present
study experienced a microbiologically documented infection
(Candida glabrata) and she belonged to the group of patients
treated with PBPCs only. The reduction ofhaematological toxicity
in our series and particularly in G-CSF plus EPO- and GM-CSF
plus EPO-treated patients translated into a global simplification of
the patients' clinical management with a significant reduction of
hospital stay compared with several other studies on PBPCT
(Gianni et al, 1989; Menichella et al, 1991; Elias et al, 1992;
Henon et al, 1992; Sheridan et al, 1992; To et al, 1992; Bensinger
et al, 1993; Chao et al, 1993; Peters et al, 1993b; Sica et al, 1993;
Pierelli et al, 1994; Shimazaki et al, 1994; Spitzer et al, 1994;
Bishop et al, 1994). None of the patients died early of CEM plus
PBPCT-related complications and this is one of the best results
reported in high-dose treatment with haematopoietic support.
None of the patients experienced long-term complications related
to the transplant procedure and those patients who underwent
second-line treatment forresidual orrecurrent disease (six patients
with ovarian cancer) showed mild and predictable haematological
and non-haematological toxicities. The median hospital charge
for a patient treated with PBPCT only was £13 500, while it was
£12 000 (this charge includes the cost of cytokine administration
in both G-CSFplus EPO- and GM-CSFplus EPO-treatedpatients)
for a patient treated with growth factors after PBPCT. The reduc-
tion of the hospital charge observed for the growth factor-treated
patients coincided with the reduction in the number of days in
hospital and with abrogation of parenteral antibiotic administra-
tion. Although fascinating, our results relative to the potentiation
ofhaematopoietic recovery obtained by growth factor administra-
tion as well as the putative majoreffectiveness ofG-CSFplus EPO
compared with GM-CSF plus EPO administration should be veri-
fied in a randomized prospective study. The results obtained in
these patients in terms of survival are encouraging, and phase III
studies will allow us to state whether this treatment may have a
role in improving survival and tumour control in patients with
high-risk cancer.
Finally, this study shows that CEM with PBPCT plus growth
factor administration is a very safe approach for delivering
chemotherapy intensification to patients with high-risk cancer
during their first-line treatment. Low non-haematological toxicity
and accelerated haematopoietic recovery render CEM with
PBPC/growth factor support an acceptable therapeutic approach in
an adjuvant or neoadjuvant setting. No relevant differences were
observed between patients treated with G-CSF plus EPO and
patients treated with GM-CSF plus EPO in terms of clinical
management. Studies are now in progress to verify which growth
factor combination produces the best immunological reconstitu-
tion following CEM and PBPCT.
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